GlobalData analyst states that long-acting GH biobetters will have an increased chance of market uptake upon entry
The lack of biosimilars in the growth hormone deficiency (GHD) treatment pipeline does not signify a missed opportunity, because superior products exist in the form of next-generation biologics known as biobetters, says an analyst with research and consulting firm GlobalData.
According to Lakshmi Dharmarajan, anaylyst, GlobalData, covering cardiovascular and and metabolic disorders, all the drugs currently in late-stage development for GHD in the seven major markets, namely the US, France, Germany, Italy, Spain, the UK and Japan, are long-acting growth hormone (GH) drugs, or GH biobetters.
Dharmarajan explains, “Despite the patent expirations of the originator drugs, there are no biosimilars in the GHD treatment pipeline. Instead, long-acting GH biobetters will have an increased chance of market uptake upon entry, as they address the unmet need for improved compliance while offering a clinical advantage over their predecessors.”
“Additionally, biobetters can be approved through the established regulatory pathways, whereas the biosimilar guidelines are still somewhat murky. While GH biobetters require more time and investment for development, the net payoff is higher when they are marketed due to their premium pricing.”
On the other hand, high biobetter prices could facilitate the adoption of GH biosimilars, because these products are expected to significantly reduce treatment costs.
However, the analyst cites the case of Sandoz’s Omnitrope, the only currently-marketed GH biosimilar, as evidence that drug uptake in this treatment space relies on more than just price and is influenced by factors such as delivery options, patient assistance programs, and company rebates to payers.
Dharmarajan continues: “Omnitrope was the first biosimilar to be approved in the global pharmaceutical space and despite having a 30 per cent lower price than Pfizer’s Genotropin (somatropin [rDNA origin]), the drug initially failed to penetrate the GHD treatment market.
The analyst concludes that to compete in such a market, biosimilar manufacturers must make a substantial investment comparable to that for the originator drugs in order to build their biosimilar brand value, a risk that only the larger pharma companies can afford to take.
EP News Bureau – Mumbai